The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Gazyva (obinutuzumab) to include a new dosing regimen for patients with follicular ...

The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...

Gazyva (obinutuzumab) is a lab-made antibody medication used for treating certain blood cancers. The FDA recently approved the combined use of Gazyva and standard therapy in adults having an active ...

Gazyva (obinutuzumab) is a brand-name intravenous (IV) infusion that’s prescribed for certain types of leukemia and lymphoma. As with other drugs, Gazyva can cause side effects. Common side effects of ...

Gazyva dosage Gazyva dosage depends on many factors, including what condition you have, what cycle of chemotherapy you are in, and other medical conditions that you may have. Your doctor will be able ...